Jiuzhou Pharmaceutical(SH:603456)2023-04-27 16:00Financial Performance - The company's operating revenue for 2022 was ¥5,445,105,154.77, representing a 34.01% increase compared to ¥4,063,181,915.60 in 2021[17]. - The net profit attributable to shareholders for 2022 was ¥920,922,206.88, a 45.28% increase from ¥633,900,939.63 in the previous year[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥927,011,401.18, reflecting a 61.70% increase from ¥573,287,858.62 in 2021[17]. - The net cash flow from operating activities for 2022 was ¥1,225,782,092.45, an 80.92% increase compared to ¥677,519,236.31 in 2021[17]. - The total assets at the end of 2022 were ¥7,913,275,762.32, a 12.40% increase from ¥7,040,423,684.10 at the end of 2021[17]. - The net assets attributable to shareholders at the end of 2022 were ¥5,296,559,223.73, which is a 15.72% increase from ¥4,577,129,753.17 in 2021[17]. - The company's operating revenue for 2022 reached 5.445 billion RMB, an increase of 34.01% compared to the previous year, primarily driven by the growth in CDMO business[25]. - Net profit attributable to shareholders for 2022 was 921 million RMB, reflecting a year-on-year increase of 45.28%, also mainly due to the expansion of CDMO business[25]. - Basic earnings per share for 2022 increased by 44.16% to 1.11 RMB per share, attributed to the rise in net profit[19]. - Diluted earnings per share rose by 46.05% to 1.11 RMB per share, driven by the increase in net profit attributable to shareholders[19]. Dividend and Shareholder Returns - The company plans to distribute a cash dividend of 4.00 CNY per 10 shares to all shareholders for the 2022 fiscal year, with no stock increases or bonus shares issued[2]. - The total cash dividend amount, including share repurchase, is RMB 406,451,648.86, which accounts for 44.14% of the net profit attributable to ordinary shareholders[151]. - The company plans to implement a shareholder return plan for the next three years (2022-2024)[127]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm, ensuring the accuracy and completeness of the financial report[2]. - The company has established a comprehensive quality management system that meets global industry standards, ensuring compliance with various international regulatory bodies[46]. - The company has continuously improved its internal control system to ensure compliance and asset security, aligning with regulatory requirements[158]. - The internal control audit report for the year was issued with a standard unqualified opinion by Tianjian Accounting Firm[160]. Research and Development - The company invested CNY 335 million in R&D in 2022, representing a 77.85% increase year-over-year[26]. - The total number of R&D personnel is 993, representing a significant investment in human resources for innovation and development[64]. - The R&D investment in CDMO projects was 19,330.76 million RMB, accounting for 3.55% of operating revenue, with a significant increase of 92.03% compared to the previous year[84]. - The company has developed multiple leading technology platforms, including chiral catalysis and continuous reaction technologies, to address client challenges[26]. - The company has established a comprehensive CDMO service platform for small molecule drugs, including pre-formulation, formulation development, quality research, and commercial production[42]. Market Expansion and Strategic Initiatives - Future outlook includes strategic plans for market expansion and potential mergers and acquisitions to strengthen its competitive position[9]. - The company is focused on expanding its market presence and enhancing its product offerings through research and development initiatives[9]. - The company aims to leverage new technologies in its product development processes to improve efficiency and effectiveness[9]. - The company is actively pursuing potential acquisitions to strengthen its market position and diversify its product portfolio[130]. - The company plans to develop a CRO platform to extend its value chain and enhance service capabilities for existing and potential clients[106]. Risk Management - The company has established a comprehensive risk management system to enhance the effectiveness of internal control and management of subsidiaries[159]. - The company faces risks related to the potential withdrawal or recall of major innovative drugs, which could impact demand for its services[110]. - The company is experiencing intensified market competition from both domestic and international pharmaceutical contract development and manufacturing organizations (CDMOs) due to new entrants and increased investment in local facilities[115]. - Environmental and safety risks are present in the production process, with potential for accidents if not managed properly, despite the company's commitment to EHS management systems[116]. Corporate Governance - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal requirements and effective decision-making[121]. - The company has established a robust investor relations management system to ensure timely and accurate communication with investors[122]. - The company has committed to fulfilling its obligations regarding the repurchase of shares and compensation for investors in case of any false statements or omissions in the IPO prospectus[184]. - The company has made commitments regarding the performance of its stock incentive plan, ensuring that any benefits obtained will be returned if there are false disclosures[187]. Environmental Responsibility - The company has implemented carbon reduction measures through the purchase of green electricity and the use of green chemical technologies[179]. - The company has developed green catalytic and synthesis technologies that significantly reduce waste emissions and energy consumption, supporting a sustainable development model[178]. - The company has established a closed-loop management system focusing on risk prevention and effective management[159]. - The company has continuously invested in environmental protection, including hardware investments and maintenance of pollution control equipment, since obtaining ISO14001 certification in 2002[178].